Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced‐stage ovarian cancer

Abstract

Objective The aim was to evaluate the effectiveness and safety of PlasmaJet™ in cytoreductive surgery in patients with advanced‐stage ovarian cancer. Methods All patients between September 2013 and January 2018 undergoing surgical cytoreduction for advanced‐stage ovarian cancer with the help of PlasmaJet™ were identified and analyzed retrospectively. Results Eighty‐seven patients diagnosed with advanced‐stage ovarian cancer underwent surgery with PlasmaJet™. Primary debulking surgery was performed in 15 cases. Fifty‐seven patients underwent interval debulking after neoadjuvant chemotherapy. Secondary and tertiary debulking was done in, respectively, 11 and three patients, and one patient underwent quaternary debulking using PlasmaJet™. In all 87 patients but one, complete resection of all macroscopic disease was obtained. PlasmaJet™ was used to remove carcinomatosis on the peritoneum, bowel serosa, intestinal mesentery, and lesions in the upper abdomen (diaphragm and liver surface). No damage to the bladder or ureter was noted in relation to the use of PlasmaJet™. Three patients developed a bowel leakage postoperatively. In one of these patients, PlasmaJet™ was used to treat tumoral implants in the affected region. Conclusions Our series suggests that the use of PlasmaJet™ is efficient and safe in obtaining complete resection of all macroscopic tumoral lesions in advanced‐stage ovarian cancer.

Adjuvant Use of PlasmaJet Device During Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: Results of the PlaComOv-study, a Randomized Controlled Trial in The Netherlands

“…These results are consistent with previous results based on case series of patients with EOC and treated with PlasmaJet. [11][12][13][14][15][16] A per-protocol analysis was performed in which 27 patients with unresectable disease were excluded, considering that the aim of the study was to examine the effectiveness of the use of the PlasmaJet during CRS.…”

“…The use of neutral argon plasma (Plasma-Jet, Plasma Surgical, Inc, Roswell, GA), in addition to standard surgical instruments may help achieve complete CRS. [10][11][12][13][14][15][16] We performed a study designed to assess whether adjuvant use of PlasmaJet would increase the proportion of complete CRS among patients with advanced-stage EOC. [17][18][19][20]…”

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review

“…As an alternative, the PJ has been used to treat advanced-stage ovarian cancer in groups of 19 patients [ 60 ], 51 patients [ 61 ], and 87 patients [ 62 ]. Carcinomatosis was removed from the peritoneum, bowel serosa, intestinal mesentery, diaphragm, and liver surface.…”

Comparing the effects of argon plasma coagulation and interferon therapy in patients with vaginal intraepithelial neoplasia: a single-center retrospective study

“…APC is an ablative technique that yields results by expelling ionized argon gas onto the target mucosal surface, thereby transferring high-frequency electrical energy to tissues, utilizing thermal effects to deactivate and dry the tissue and cause coagulation and necrosis [ 19 ]. The first use of argon plasma energy in gynecological surgery was reported by Madhuri et al in 2010, to treat ovarian cancer, ovarian cyst, peritoneal cancer, endometriosis, and myoma [ 34 ]. Until now, the non-invasive physical plasma (NIPP) treatment using a next-generation and non-thermally electrosurgical argon plasma device was widely used in precancerous and cancerous lesions, such as CIN [ 35 ].…”